The Kratom Retailer's Tax Guide: 280E, the State Patchwork, and the 7-OH Question

Kratom retailers get treated like cannabis businesses by almost everyone except the tax code. Banks decline them. Processors hold their funds. And more than once, we have seen a prior preparer quietly apply a 280E-style framework to a kratom return - disallowing ordinary deductions out of caution, habit, or confusion. That instinct is wrong, and it costs the operator real money. Kratom is not a federally scheduled substance. Section 280E, which disallows deductions only for trafficking in substances "within the meaning of schedule I and II of the Controlled Substances Act," does not apply to it.

We say that with the same statutory discipline we bring to our cannabis work, where the IRS has long asserted the disallowance against state-legal operators - a position we have publicly challenged. For kratom, there is no assertion to challenge. The substance is not on any federal schedule, the trigger language is not satisfied, and the analysis ends there.

The 2016 Scheduling Attempt, and Why It Still Matters

Kratom is the leaf of Mitragyna speciosa, and its principal active alkaloids are mitragynine and 7-hydroxymitragynine. In August 2016, the DEA published a notice of intent to place both alkaloids on Schedule I on an emergency basis. The public response was unusual in both volume and composition: tens of thousands of comments, letters from members of Congress, and pushback from researchers. In October 2016, the DEA withdrew the notice. Emergency scheduling withdrawals are rare, and this one left kratom exactly where it had been - unscheduled at the federal level.

That history matters for two reasons. First, it settles the current tax analysis: no schedule, no 280E. Second, it proves the ground can move. An agency that proposed Schedule I once can propose it again, and a kratom operator's structure should be built with that possibility priced in. We come back to that below.

The Tax Treatment That Follows

Because kratom is unscheduled, a kratom retailer is entitled to the ordinary tax treatment of any lawful trade or business. Under IRC 162, ordinary and necessary business expenses are fully deductible: rent, payroll, marketing, professional fees, processing fees, software, insurance. Under IRC 199A, pass-through owners are eligible for the 20% qualified business income deduction, subject to the standard wage and income limits. Inventory accounting follows IRC 471, and operators under the section 471(c) small business threshold (currently approximately $29 million in average annual gross receipts) have flexibility in method. COGS includes product acquisition, inbound freight, testing, packaging, and fulfillment - recognized on the return like any other retailer's costs.

The "not for human consumption" label that appears on much of the market's packaging does not change any of this. Income from selling kratom is ordinary income. The costs of acquiring and shipping it are deductible costs. The disclaimer is a regulatory posture, not an accounting method - and as we explain below, it is not a shield on the regulatory side either.

The Map Under Your Feet

The federal tax answer is stable. Almost nothing else about the kratom landscape is, and a retailer's risk profile is defined by layers that have nothing to do with the IRS.

The FDA has never approved kratom for any use. It has issued import alerts, seized shipments, and sent warning letters to vendors making disease claims. A kratom business that markets with health claims is inviting exactly the enforcement attention the industry's labeling conventions exist to avoid.

Concentrated 7-hydroxymitragynine products are drawing their own scrutiny. In 2025, the FDA publicly recommended scheduling concentrated 7-OH products - the potent isolate tablets and shots that have proliferated in convenience stores - while distinguishing them from whole-leaf kratom. The DEA has not acted on that recommendation as of this writing, but several states have already moved to ban or restrict 7-OH products specifically, in some cases even where leaf kratom remains legal. If federal scheduling of 7-OH isolates ultimately happens, retailers carrying those SKUs would face a different analysis on that product line than on leaf and powder. Every kratom retailer should be tracking this docket, and we track it for our clients.

The state patchwork is real and moving. A handful of states prohibit kratom outright. A growing list regulates it through Kratom Consumer Protection Acts, with age limits, labeling requirements, testing standards, and registration obligations. Our home state sits on the regulated list: Oregon passed its own Kratom Consumer Protection Act in 2022, restricting sales to buyers 21 and over and setting testing and labeling standards modeled on the state's cannabis and hemp programs. Local ordinances ban kratom in specific counties and cities even where state law allows it. A multi-state shipper needs a current map of where it can lawfully sell, refreshed on a real cadence, because the map changes between legislative sessions.

Sales Tax Nexus: The Exposure That Actually Accrues

The most common dollar-denominated problem we find in a kratom retailer's books is not federal at all. It is uncollected sales tax. An Oregon retailer starts with a home-field advantage here - Oregon imposes no general state sales tax, so in-state sales generally create no Oregon sales tax collection obligation - but that comfort ends at the state line. Since South Dakota v. Wayfair, economic nexus thresholds - most states set the trigger around $100,000 in gross receipts, and some retain a 200-transaction test - create registration and collection obligations in states the operator has never set foot in. A kratom brand shipping nationally can build obligations in dozens of states within two years, and back assessments compound with penalties and interest. The fix is the same one we deploy for peptide retailers: a nexus study, voluntary disclosure agreements where exposure already exists, and tax collection software wired into the order system going forward.

Entity Choice as Risk Containment

For an ordinary business, entity selection is mostly a tax-efficiency question. For a business whose product an agency once tried to schedule, it is a containment question - the same analysis we laid out in our article on grey-market businesses. If the federal status of kratom or a kratom-derived isolate changes, the consequences should land inside the business entity, not on the owner's personal return. That logic often points toward C corporation treatment or, at minimum, a structure that separates the kratom product line from other operations so that a regulatory shift in one line does not contaminate the whole enterprise. It also points toward clean books from day one: if a deduction-limiting regime ever did attach to a portion of the business, the operators with properly segregated accounting would be the ones positioned to defend their numbers.

Banking and Processing Friction

Kratom remains a high-risk category for most payment processors. Operators commonly face elevated processing rates, rolling reserves, and account terminations with little notice, and policies vary processor to processor. None of this changes the tax treatment, but it changes cash flow planning, and the books need to track reserve balances and held funds accurately so that revenue recognition and cash availability are never confused.

What Calyx Does for Kratom Operators

Entity formation built for containment, not just efficiency. Multi-state sales tax registration, voluntary disclosure where back exposure exists, and ongoing remittance. Monthly accounting with product-line separation between kratom, 7-OH isolates, and any other SKUs, so a regulatory change in one line never muddies the rest. Monitoring of DEA and FDA activity on mitragynine and 7-hydroxymitragynine as part of the ongoing engagement. Federal and state return preparation, amended returns where a prior preparer wrongly limited deductions, and audit representation if a return we prepared draws a question.

The Position, Restated

Kratom is not a controlled substance within the meaning of Schedule I or Schedule II of the federal Controlled Substances Act. Section 280E does not apply to a kratom business, and a kratom retailer is entitled to full ordinary deductions, standard inventory accounting, and IRC 199A eligibility. The risks that deserve planning attention are the moving ones: the state patchwork, the FDA's posture on concentrated 7-OH products, sales tax nexus, and the possibility - proven live in 2016 - that the federal map changes. We structure kratom businesses so the tax position is defensible today and the entity can absorb whatever the regulatory map does next.

If your kratom business has been treated like a cannabis business on its tax return, the return is wrong and likely correctable. Contact us through the Calyx CPA site to start a conversation.

This article is intended for informational purposes only and does not constitute legal, tax, or medical advice.